Form 4: Edesa Biotech CEO Acquires 10,444 Shares

Edesa Biotech's CEO, Pardeep Nijhawan, reported the acquisition of 10,444 common shares through a restricted share unit grant.

Summary

• Pardeep Nijhawan, CEO, Director, and 10% Owner of Edesa Biotech, Inc. (EDSA), acquired 10,444 common shares.
• The acquisition occurred on January 5, 2026, as a grant of restricted share units (RSUs) that vested immediately upon grant.
• The shares were granted at a price of $0 under the Issuer's 2019 Equity Incentive Compensation Plan.
• Following this transaction, Nijhawan directly beneficially owns 501,822 common shares.
• Indirect beneficial ownership includes 341,702 shares held by Pardeep Nijhawan Medicine Professional Corporation, 32,609 by The New Nijhawan Family Trust 2015, 32,013 by The Digestive Health Clinic Inc., and 53,104 by 1968160 Ontario Inc.

Sentiment

Score: 6

Explanation: Slightly positive due to increased insider ownership, which generally signals confidence, although it's a compensation grant rather than an open market purchase.

Positives

• Increased insider ownership aligns management interests with shareholders.
• The grant of restricted share units is part of a structured compensation plan, indicating ongoing commitment from the CEO.

Future Outlook

NA

Industry Context

This is a routine insider transaction, common across all industries, reflecting executive compensation structures rather than specific industry trends.

Related Party Transactions

• Pardeep Nijhawan indirectly holds shares through entities he wholly owns (Pardeep Nijhawan Medicine Professional Corporation, The Digestive Health Clinic Inc., 1968160 Ontario Inc.) and a family trust (The New Nijhawan Family Trust 2015) where he is a co-trustee. These are disclosed as part of his beneficial ownership.

Stakeholder Impact

• Shareholders may view the increased insider ownership as a positive sign of management's alignment with shareholder interests.
• Employees are not directly impacted by this specific transaction, though it relates to executive compensation.

Key Dates

Keywords

Edesa Biotech, EDSA, Pardeep Nijhawan, Insider Transaction, Form 4, Restricted Share Units, Equity Incentive Plan, CEO, Director, 10% Owner